Skip to main content
. 2021 Dec 9;24:148–159. doi: 10.1016/j.omto.2021.12.006

Table 1.

Nivolumab content of the nivolumab-PEG-PCL nanoparticles of various PEG-PCL amounts used in the nanoprecipitation process

Ratio of PEG-PCL to Nivolumab, % w/w Nivolumab Content, % w/wa
20 2.5 ± 0.11
40 3.6 ± 0.08
60 3.8 ± 0.06
80 3.7 ± 0.09
a

The SD value is for the mean trastuzumab content (% w/w) obtained from three measurements.